Alison Hamilton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alison Hamilton has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Stephen S. G. Ferguson
J. Allyn Taylor Centre for Cell Biology, Robarts Research Institute, and the Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada
2 shared publications - Gerald Werner Zamponi
University of Calgary
1 shared publication - Jessica L Esseltine
The J. Allyn Taylor Centre for Cell Biology, Robarts Research Institute, The University of Western Ontario, 100 Perth Dr, London, Ontario N6A 5 K8, Canada
1 shared publication - Rebecca A DeVries
The J. Allyn Taylor Centre for Cell Biology, Robarts Research Institute, The University of Western Ontario, 100 Perth Dr, London, Ontario N6A 5 K8, Canada
1 shared publication - Sean P. Cregan
Neuroscience Program, University of Western Ontario, London, ON, Canada
1 shared publication
Latest Publications
- Open Access
- 24 March 2015
- Published by Springer Nature in Molecular Brain
- Vol. 8 (1) , 1-9
Glutamate receptors function as scaffolds for the regulation of β-amyloid and cellular prion protein signaling complexes
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects 36 million people worldwide, but currently has no effective treatment options. One of the original hallmarks of AD are plaques comprised of beta amyloid (Aβ) and neurofibrillary tangles comprised of phosphorylated Tau protein. However, it is soluble oligomeric Aβ which is more closely correlated with cognitive decline and is therefore considered to be the neurotoxic species. Oligomeric Aβ has recently been shown to form complexes with the glycosylphosphatidylinositol (GPI)-anchored membrane protein, cellular prion protein (PrPc), and these complexes are believed to play an important role in the progression of AD pathogenesis. Glutamate, the major excitatory neurotransmitter is responsible for mediating learning and memory under normal physiological conditions. However, the dysregulation of glutamatergic signaling has also been implicated in a number of neurodegenerative diseases including AD. Glutamate acts via both ionotropic glutamate receptors (iGluR) and metabotropic glutamate receptors (mGluR), each of which have been implicated in AD. There is now growing evidence to suggest that mGluR5 may contribute the AD pathogenesis by acting as scaffolds for the PrPc/Aβ oligomer complex, enabling the propagation of neurotoxic signaling in AD. In addition, PrPc and Aβ oligomer signaling via NMDARs may also contribute to AD pathology. The current review overviews our current understanding of the role of PrPc and Aβ oligomers in regulating glutamate receptor signaling, as well as highlights the importance of understanding these signaling complexes to develop more effective therapeutic strategies to treat AD.
- 24 March 2015
- Published by Springer Nature in Molecular Brain
- Vol. 8 (1) , 1-9
Open AccessGlutamate receptors function as scaffolds for the regulation of β-amyloid and cellular prion protein signaling complexes
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects 36 million people worldwide, but currently has no effective treatment options. One of the original hallmarks of AD are plaques comprised of beta amyloid (Aβ) and neurofibrillary tangles comprised of phosphorylated Tau protein. However, it is soluble oligomeric Aβ which is more closely correlated with cognitive decline and is therefore considered to be the neurotoxic species. Oligomeric Aβ has recently been shown to form complexes with the glycosylphosphatidylinositol (GPI)-anchored membrane protein, cellular prion protein (PrPc), and these complexes are believed to play an important role in the progression of AD pathogenesis. Glutamate, the major excitatory neurotransmitter is responsible for mediating learning and memory under normal physiological conditions. However, the dysregulation of glutamatergic signaling has also been implicated in a number of neurodegenerative diseases including AD. Glutamate acts via both ionotropic glutamate receptors (iGluR) and metabotropic glutamate receptors (mGluR), each of which have been implicated in AD. There is now growing evidence to suggest that mGluR5 may contribute the AD pathogenesis by acting as scaffolds for the PrPc/Aβ oligomer complex, enabling the propagation of neurotoxic signaling in AD. In addition, PrPc and Aβ oligomer signaling via NMDARs may also contribute to AD pathology. The current review overviews our current understanding of the role of PrPc and Aβ oligomers in regulating glutamate receptor signaling, as well as highlights the importance of understanding these signaling complexes to develop more effective therapeutic strategies to treat AD.
- Open Access
- 29 May 2014
- Published by Springer Nature in Molecular Brain
- Vol. 7 (1) , 40
Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease
Alzheimer’s disease (AD) pathology occurs in part as the result of excessive production of β-amyloid (Aβ). Metabotropic glutamate receptor 5 (mGluR5) is now considered a receptor for Aβ and consequently contributes to pathogenic Aβ signaling in AD.
- 29 May 2014
- Published by Springer Nature in Molecular Brain
- Vol. 7 (1) , 40
Open AccessMetabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease
Alzheimer’s disease (AD) pathology occurs in part as the result of excessive production of β-amyloid (Aβ). Metabotropic glutamate receptor 5 (mGluR5) is now considered a receptor for Aβ and consequently contributes to pathogenic Aβ signaling in AD.